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Abstract
Background: Panic disorder (PD) is a common, severe and persistent mental disorder, associated
with a high degree of distress and occupational and social disability. A substantial proportion of the
population experiences subthreshold and mild PD and is at risk of developing a chronic PD. A
promising intervention, aimed at preventing panic disorder onset and reducing panic symptoms, is
the 'Don't Panic' course. It consists of eight sessions of two hours each. The purpose of this study
is to evaluate the effectiveness of this early intervention – based on cognitive behavioural principles
– on the reduction of panic disorder symptomatology. We predict that the experimental condition
show superior clinical and economic outcomes relative to a waitlisted control group.
Methods/design: A pragmatic, pre-post, two-group, multi-site, randomized controlled trial of the
intervention will be conducted with a naturalistic follow-up at six months in the intervention group.
The participants are recruited from the general population and are randomized to the intervention
or a waitlist control group. The intervention is offered by community mental health centres.
Included are people over 18 years of age with subthreshold or mild panic disorder, defined as
having symptoms of PD falling below the cut-off of 13 on the Panic Disorder Severity Scale-Self
Report (PDSS-SR). Primary outcomes are panic disorder and panic symptoms. Secondary
outcomes are symptoms of agoraphobia, anxiety, cognitive aspects of panic disorder, depressive
symptoms, mastery, health-related quality of life, and cost-effectiveness. We will examine the
following variables as potential mediators: cognitive aspects of panic disorder, symptoms of
agoraphobia, anxiety and mastery. Potential moderating variables are: socio-demographic
characteristics, panic disorder, agoraphobia, treatment credibility and mastery.
Discussion: This study was designed to evaluate the (cost) effectiveness of an early intervention
based on cognitive behavioural principles. The strong external validity is one of the strengths of the
study design.
Trial registration: Current Controlled Trials ISRCTN33407455.
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Panic disorder (PD) affects 2% to 3% of the adult popula-
tion each year [1-3], and is associated with a large burden
of disease, considerable medical consumption and exten-
sive loss of productivity [4-7]. The incidence of PD is high
(about 35% of all PD cases are new cases, having emerged
only in the last year; [1]), indicating the importance of
prevention and early intervention in PD.
A substantial proportion of the population suffers from
subthreshold PD [8-10]. Subthreshold PD can be defined
as the presence of some symptoms of PD, not meeting the
DSM-IV diagnostic criteria. In a study reported by Norton,
Dorward and Cox [11], 35.9% of the 256 presumably nor-
mal subjects reported experiencing one or more panic
attacks in the past year, with 22.7% experiencing one or
more panic attacks within the past three weeks. These sub-
jects may be at risk of developing full-blown PD [12,13].
PD sufferers are often not recognized as such [4]. Further-
more, although there are effective treatments for PD [14],
PD sufferers do not always receive empirically supported
treatments; even if this were the case, the proportion of
burden averted would still be low [15]. In addition, it usu-
ally takes many years before treatment is sought, and
when not properly treated the prognosis is poor and the
disorder may become chronic [16]. Prevention and early
intervention in PD are therefore of great interest, and a
panic prevention and early intervention program deliv-
ered to subjects with subthreshold or mild PD may
decrease current panic disorder symptomatology.
Studies on prevention and early intervention in anxiety
disorders indicate that prevention of anxiety disorders
through cognitive-behavioural interventions can be suc-
cessful [17-19]. Only a few studies have been conducted
in this field. Gardenswartz and Craske [20] tested a pre-
vention program for panic disorder. Participants consisted
of college students who had experienced a panic attack in
the last 12 months and had at least moderate anxiety sen-
sitivity (ASI score of 16 or higher; [21]), but did not meet
the criteria for panic disorder (CIDI; [22]). They were ran-
domly assigned to either a one-day prevention workshop
(n = 55) or a wait-list control (n = 66). The one-day (five-
hour) workshop entailed psycho-education, breathing
retraining, cognitive restructuring, interoceptive exposure
and 'in vivo' exposure. At six-month follow-up nine par-
ticipants (13.6%) from the wait-list group and only one
participant (1.8%) from the workshop group had devel-
oped panic disorder, indicating a favourable treatment
response.
In a study by Swinson, Soulios, Cox, and Kuch [23], 33
adults with panic attacks seen in two emergency rooms
were randomly assigned to groups receiving reassurance
(n = 16) or exposure instruction (n = 17). Subjects who
had received the exposure instruction significantly
improved over the six-month follow-up period for symp-
toms of depression, avoidance, and panic frequency,
whereas subjects receiving reassurance did not improve
for any of these variables.
Despite methodological limitations, such as limited gen-
eralizability, small sample size and short follow-up peri-
ods, the results of these studies suggest that prevention of
panic disorder is a promising option.
The aim of this study is to examine the effectiveness of an
early intervention for panic symptoms in a sample of self-
referred people presenting with subthreshold or mild PD
in a randomized controlled trial. We predict that the inter-
vention will show superior effects in reducing panic disor-
der symptomatology, compared to a waitlisted control
group. Furthermore, an economic analysis will be per-
formed to assess the cost-effectiveness of the intervention.
Methods
Study design
The study was designed as a pragmatic, multi-site, rand-
omized controlled trial of the 'Don't Panic' course versus
a wait-list control group. Measurements were taken at
baseline measurement (T0) followed by a posttest meas-
urement after three months (T1). To monitor effect main-
tenance over time, the experimental group underwent a
prolonged follow-up measurement nine months after
baseline, i.e., six months after the end of the intervention
(T2). The study was designed to mimic the Dutch health
care system as naturalistically as possible in terms of
patient recruitment and the manner in which intake,
offering the intervention, and monitoring outcomes are
conducted. This was done to enhance external validity.
The randomization took place after administration of the
International Neuropsychiatric Interview Plus (MINI-
Plus; [24]), and was carried out centrally by an independ-
ent third party. A blocked randomization scheme was
used, stratified by mental health centre, subthreshold PD
versus mild PD, and by presence versus absence of co-
occurring agoraphobia. The latter was included because it
was assumed that agoraphobia may be a prognostically
relevant factor for outcome in PD. This procedure ensures
that participants with and without PD or agoraphobia
were equally distributed across both trial arms. See Figure
1 for participants' flow through the study. The trial proto-
col was approved by an independent medical ethics com-
mittee (METIGG).
Sample size
Power analysis indicated that 129 participants per condi-
tion are required in order to detect a difference in symp-
tom reduction, equivalent to a standardized effect size ofPage 2 of 9
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power of (1-beta) = 0.80.
Study sample
Participants were recruited from the general adult popula-
tion in the Netherlands. They were eligible when over 18
years of age and presenting with subthreshold or mild
panic disorder, defined as having symptoms of PD falling
below the cut-off of 13 on the Panic Disorder Severity
Scale-Self Report (PDSS-SR) [25,26]. Exclusion criteria
were more severe PD (PDSS-SR ≥ 13), other current severe
psychiatric symptoms or social problems, suicidal inten-
Participants' flow through the studyFigure 1
Participants' flow through the study. PDSS: Panic Disorder Severity Scale-Self Report, MINI: Mini-International Neuropsy-
chiatric Interview-Plus.Page 3 of 9
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ipation in the group course, and current psychological
treatment for PD-related complaints. Other exclusion cri-
teria were illness requiring immediate medical attention,
and inability to function independently as well as in a
group. People meeting one of the exclusion criteria were
advised to seek regular treatment. If a participants used
medication for anxiety or depression, it was agreed not to
change the medication during the study period. Following
a thorough explanation of the study procedures, written
informed consent was obtained.
Recruitment
Participants were recruited from the general population
through media announcements and via the internet. For
screening, the standard procedures employed by the Com-
munity Mental Health Centers were used. Firstly, people
who showed interest were given more information about
the course and the study. They also had an initial screen-
ing interview by telephone to ascertain the presence of
panic symptoms. Secondly, potential participants had an
interview with an experienced psychologist from a Com-
munity Mental Health Centre. In this interview, the exclu-
sion criteria as described above were checked. In addition,
potential participants were interviewed by trained inter-
viewers from the Trimbos Institute (Netherlands Institute
of Mental Health and Addiction) using the MINI-Plus
[24]. This was done to assess the DSM-IV PD status, the
presence of current co-morbid agoraphobia, and to
exclude the presence of current severe major depressive
disorder.
Interventions
We developed an early intervention for panic symptoms,
called the 'Don't panic' course. The course is based on cog-
nitive-behavioural principles and makes use of interven-
tions that have appeared effective in the treatment of the
full-blown disorder [27-29]. This intervention was devel-
oped specifically for adults. It consists of eight weekly ses-
sions of two hours each in groups of six to 12 participants.
The 'Don't panic' course makes use of a course manual
[30], to be used by the psychologist and prevention
worker offering the intervention, and an accompanying
workbook for the participants [31]. The course instructors
received a one-day training in offering the course and
working with the course manual, to ensure integrity of the
intervention delivery. Participants were taught to examine
their panic attacks and the possible causes, to use tech-
niques to influence their anxiety, and to develop skills to
improve how they cope with panic attacks. The course
includes (a) a psycho-educational element about the
nature and physiology of anxiety and panic attacks, (b)
life-style changes to improve physical condition, (c) stress
management to prevent constant tension by learning
effective ways to cope with stress, (d) relaxation training
to reduce physiological arousal, (e) cognitive restructur-
ing to challenge and correct dysfunctional cognitions of
panic and anxiety, (f) interoceptive exposure to reduce the
fear of somatic sensations, (g) 'in vivo' exposure to reduce
agoraphobic avoidance, and (h) techniques aimed at
relapse prevention. During the course the participants had
to evaluate their progress. After three months following
completion of the course a booster session was offered.
Each session was structured to include a discussion of
homework assignments, feedback, rehearsals, informa-
tion about the upcoming topic and practical skills train-
ing. The intervention was extensively pilot-tested before
entering the clinical trial stage.
The control condition consisted of a waiting list. Wait-
listed people were told that they could start the course
after four months. They were not kept waiting for the
extended follow-up for ethical reasons.
Instruments
The instruments used are well validated and frequently
applied in international studies. Table 1 represents the
measurements conducted at the different assessment
times. Most of the self-report questionnaires were used for
all three measurements and completed at home. The
MINI-Plus was conducted by telephone at T0 and T1.
Primary outcome measures
Primary outcome measures include the severity of panic
symptoms and PD diagnoses.
Severity of panic symptoms
For severity of panic symptoms the Dutch adaptation of
the PDSS-SR [25,32] was used. The PDSS-SR contains
Table 1: Instruments at different assessment times
T0 T1 (3 months) T2 (9 Months)
PDSS-SR X X X
MINI-Plus X X
MI X X X
HADS-Anx X X X
PAI X X X
BDI-II X X X
Mastery X X X
EQ-5D X X X
TIC-P X X X
Evaluation X
Demografics X
AUDIT X
TCQ X
PDSS-SR:  Panic Disorder Severity Scale-Self Report, MINI-Plus: Mini 
International Neuropsychiatric Interview-Plus, MI: Mobility Inventory, 
HADS-Anx: Hospital Anxiety and Depression Scale, subscale Anxiety, 
PAI: Panic Appraisal Inventory, BDI-II: Beck Depression Inventory-
second edition, EQ-5D: EuroQol Questionnaire, TIC-P: Trimbos and 
Institute of Medical Technology Assessment Questionnaire on Costs 
Associated with Psychiatric Illness, AUDIT: Alcohol Use Disorders 
Identification Test, TCQ: Treatment Credibility Questionnaire.Page 4 of 9
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panic disorder and associated symptoms: 1) frequency of
panic attacks; 2) distress during panic attacks; 3) anticipa-
tory anxiety (worry about future panic attacks); 4) agora-
phobic fear and avoidance; 5) interoceptive fear and
avoidance (i.e., apprehension and avoidance of bodily
sensations); 6) impairment of or interference in work
functioning; and 7) impairment of or interference in
social functioning. The PDSS-SR generates a total score
ranging from 0 to 28, with a higher score indicating more
severe panic symptoms. The questionnaire has good psy-
chometric properties (Cronbach's alpha = 0.92; intraclass
correlation coefficient = 0.81) [33]. A cut-off score of eight
may discriminate between the presence or absence of cur-
rent DSM-IV panic disorder [25,32] and a cut-off score of
thirteen may discriminate between mild and severe panic
disorder [26,32].
Diagnosis
To assess the DSM-IV panic disorder status the Dutch ver-
sion of MINI-Plus [24,34] was used. The MINI-Plus is a
short, structured, diagnostic interview for DSM-IV and
ICD-10 psychiatric disorders, designed for use by profes-
sional interviewers. Validation of the MINI in relation to
the Structured Clinical Interview for DSM-III-R Patient
Version and the Composite International Diagnostic
Interview showed good to very good kappa values [24]. To
exclude serious major depressive disorder this section was
supplemented with the Sheehan Disability Scale [35].
Subjects who reported at least two areas of role function-
ing with severe role impairment due to a depressive disor-
der were excluded from the study. The interviews were
conducted by experienced interviewers who received one
day's training. The interviews were conducted by tele-
phone, as several findings provide qualified justification
for this mode of assessing psychiatric disorders [36,37].
The interviewers were blind with respect to the randomi-
zation status of the participants.
Secondary outcome measures
Secondary outcome measures include symptoms of agora-
phobia, anxiety symptoms, cognitive measure for panic,
depressive symptoms, perceived control, quality of life
and cost-effectiveness.
Symptoms of agoraphobia
For symptoms of agoraphobia the Dutch adaptation of
the Mobility Inventory (MI; [38,39]) was used. The MI
assesses agoraphobic avoidance. The total score ranges
from 1 to 5, with a higher score indicating more avoid-
ance. The MI has been found to have good test-retest reli-
ability, high internal consistencies, and reasonably
concurrent validity [38,39].
Anxiety symptoms
The subscale for anxiety of the Dutch version of the Hos-
pital Anxiety and Depression Scale (HADS) was used to
indicate the possible presence of anxiety states. The HADS
was developed as a brief self-report screening scale to
detect states of depression and anxiety in the setting of a
medical out-patient clinic [40]. A validation study of the
Dutch version of the HADS by Spinhoven et al. [41] con-
firmed the two-factor structure and showed α's ranging
from 0.71 – 0.90 for the total scale and both subscales.
The subscale for anxiety consists of seven items with a
score range of 0–21. A high score means a higher state of
anxiety.
Cognitive measure for panic
As a cognitive measure for panic disorder the Dutch ver-
sion of the Panic Appraisal Inventory [42,43] was used.
The PAI measures cognitive aspects of panic disorder, such
as (PAI-anticipation) perceived likelihood of panic occur-
rence, (PAI-consequences) perceived negative conse-
quences of panic occurrence, and (PAI-coping) perceived
self-efficacy in coping with panic. Each of the three sub-
scales of the PAI consists of 15 items; the scale score ranges
from 0 to 100, and a higher score means a more negative
cognitive state. The PAI has excellent psychometric prop-
erties; it has been shown to be reliable, valid and quite
sensitive to change after therapy [42,43].
Depressive symptoms
The Dutch version of the Beck Depression Inventory, sec-
ond edition, (BDI-II; [44,45]) was used to assess depres-
sive symptoms. The BDI-II is a 21-item self-report
questionnaire for assessing the severity of depressive
symptoms in the past week. The total score ranges from 0
to 63. A high score reflects a higher depression level. The
BDI-II has good psychometric properties [45,46].
Perceived control
The Dutch version of the Mastery-Scale [47] was used to
assess locus of control; a higher rating means greater inter-
nal locus of control, indicating more feelings of mastery.
The total score ranges from 5 to 25. The Mastery-Scale has
good psychometric properties [47].
Quality of life
As a measure for quality of life the Dutch version of the
EuroQol Questionnaire (EQ-5D) [48-50] was used. It
contains five dimensions (mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression), each of
which is rated by the respondent as causing 'no problems',
'some problems', or 'extreme problems'. The EQ-5D gen-
erates a total of 243 unique health states, each of which is
associated with a utility score ranging from 0 (poor
health) to 1 (perfect health). The EQ-5D is a validatedPage 5 of 9
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life [48-50].
Cost-effectiveness
For economic evaluation the following costs were exam-
ined, using parts of the Trimbos and Institute of Medical
Technology Assessment Questionnaire on Costs Associ-
ated with Psychiatric Illness (TIC-P)[51]: costs directly
related to health care, indirect health care related costs
(out-of-pocket costs, costs of informal care), direct costs
outside health care (monetary value of production losses
caused by absence and reduced productivity).
Additional measures
To examine the feasibility and acceptability of the inter-
vention, questionnaires were used to evaluate the course
by the participants (e.g., questions to evaluate organiza-
tional aspects, coaching, content, group sessions, and
workbook) at posttest.
To collect demographic information pertaining to the par-
ticipants, questions concerning gender, age, nationality,
living situation, education and occupation were added to
the self-report questionnaires.
Furthermore, the AUDIT (Alcohol Use Disorders Identifi-
cation Test)[52] was used to assess alcohol use and the
TCQ (Treatment Credibility Questionnaire)[53] was used
for treatment credibility. Both questionnaires have good
psychometric properties [54,55] and were used as possi-
ble predictor variables.
Analyses
All analyses were conducted in agreement with the inten-
tion to treat principle [56], hence all participants were
analyzed in the condition to which they were rand-
omized, and missing endpoints at follow-up were
imputed using a regression model with the best available
predictors of outcome and the best predictors for dropout.
The first set of predictors is required to get the most precise
estimates for the missing values; the latter to correct for
bias that may stem from differential loss-to-follow-up
associated with T0 variables [57].
In all analyses on effectiveness, we controlled for the clus-
tering of data caused by the multi-site character of the
study. Clustering violates the assumption of independ-
ence of observations, and may thus affect standard errors
and P values. So-called 'robust standard errors' and correct
P values were obtained using the first-order Taylor series
linearization method. All analyses were conducted with
Stata 9.0 [58].
For the primary outcome on PDSS-SR, a Gaussian regres-
sion model was used to test the hypothesis of superior
intervention effects in the experimental arm compared to
the waitlist control group. We calculated between-group
effect sizes at posttest by subtracting the mean posttest
score of each condition and dividing the difference by the
pooled standard deviation (Cohen's d). In the field of psy-
chological interventions, effect sizes in the range of 0.00
to 0.32 are regarded as small, while effect sizes of 0.33 to
0.55 are moderate, and effect sizes of 0.56 to 1.2 are large
[59].
As primary outcome we also compared the proportion of
participants manifesting a clinically significant change on
the PDSS-SR (responders) across the two groups. Clini-
cally significant change was defined according to the crite-
ria proposed by Jacobson and Truax [60]: a change should
move from a dysfunctional distribution to a functional
one, and the change should be statistically reliable in the
sense that the observed change cannot be put down to
measurement error in the PDSS-SR. Because we studied a
population with subthreshold and mild PD, we consid-
ered scores below one standard deviation of the mean pre-
test score on the PDSS-SR as falling within the functional
range [61]. This binary outcome was then used to obtain
the odds ratio (OR) using a logistic regression of the
binary outcome on the intervention dummy and the
numbers-to-be-treated (NNT) using Gaussian regression.
The sample can be divided in two groups: people with rel-
atively mild manifestations of MINI-DSM-IV panic disor-
der and those with subthreshold manifestations not
meeting the diagnostic criteria. When we focus on the lat-
ter group: people at risk of developing panic disorder, we
can look at how many of these persons developed PD
meeting the diagnostic criteria of the DSM-IV at T1. When
we pay attention to the group with mild PD, we can see
how many of these persons became PD-free at T1. For the
primary outcome on the MINI-Plus we compared the pro-
portion of success across the two groups. Success was
defined as: (a) the participant had no PD at T0 and stayed
PD free at T1 or (b) the participant had mild PD at T0 and
no PD at T1. This yields a binary outcome where failure is
coded 0, and success is coded 1. In a next step, this binary
outcome was used to obtain the OR and the NNT.
The demographic and clinical characteristics of respond-
ers versus non-responders, and success versus failure, were
compared using Student's t test for independent groups or
Pearson's chi-squared tests when appropriate.
For the secondary outcomes on continuous measurement
scales, a Gaussian regression model was used to test the
hypothesis of superior intervention effects in the experi-
mental arm compared to the wait-list control group. Fur-
thermore, the between-group effect sizes (Cohen's d) were
calculated. To test the maintenance of the effects at six-Page 6 of 9
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lyze the difference in mean score of the self-report meas-
ures in the experimental group from T0 to T1, T0 to T2
and T1 to T2.
To provide a more comprehensive picture of the effects of
the intervention, results for the outcomes will also be pre-
sented for completers only (defined as participants who
attended at least six sessions).
The following variables will be examined as potential
mediators: cognitive aspects of panic disorder, symptoms
of agoraphobia, anxiety and mastery. Furthermore, poten-
tial moderating variables (e.g., socio-demographic charac-
teristics, panic disorder, agoraphobia, treatment
credibility and mastery) will be analyzed.
The following costs are examined for economic evalua-
tion: costs directly related to health care, indirect health
care related costs (out-of-pocket costs, costs of informal
care), direct costs outside health care (monetary value of
production losses caused by absence and reduced produc-
tivity), as measured with the TIC-P. The mean total costs
for each of the conditions at baseline and T1 were calcu-
lated. Then the pre-post difference in costs were calculated
to obtain the increase (or decrease) of costs over time in
each of the conditions. First, we observed how many par-
ticipants presented with a clinically significant change on
the PDSS-SR across the two groups. The incremental cost-
effectiveness ratio (ICER) was calculated as the incremen-
tal costs for a health gain of a clinically significant change
over three months. Next, we observed how many people
stayed PD free at T1. The ICER was calculated as the incre-
mental costs for a health gain of a PD-free survival over
three months. Furthermore, we calculated the incremental
cost-utility ratio (ICUR) across the experimental and con-
trol condition. The ICUR represents the incremental costs
(or savings) per QALY (Quality Adjusted Life Years,
assessed with the EQ-5D) gained in the experimental con-
dition relative to the control condition. By calculating
ICUR the results can be compared to other health care
interventions. In all cases, uncertainty was assessed by
means of non-parametric bootstrapping (2,500 times) of
the data of the individual respondents.
All tests were conducted using a two-sided significance
level at α < 0.05.
Discussion
The purpose of this study is to evaluate the effectiveness of
this early intervention based on cognitive behavioural
principles on the reduction of panic disorder symptoma-
tology. Furthermore, cost-effectiveness of the intervention
is evaluated. We predicted that the experimental condi-
tion would show superior effects in reducing panic symp-
toms, improving quality of life and will be cost-effective
despite the additional costs introduced by offering the
'Don't Panic' intervention in the first place. This may be
regarded to be an important finding, because, to our
knowledge, this is the first study that examines the effec-
tiveness of an early intervention for self-referred adults
with subthreshold or mild panic disorder, offered by com-
munity mental health centres.
Strengths and limitations
We changed the original protocol by including people
with mild PD (PDSS < 13) and, as a consequence, not
excluding participants with PD according to the MINI-
Plus. People with mild PD are known to be shy in asking
professional help. A low threshold intervention may
appear accessible and acceptable for these people. In the
Dutch mental health care system people with subthresh-
old or mild mental disorders are usually offered courses as
a first step in a stepped-care model in mental health [62-
64]. To strengthen the external validity of the trial we
decided to include people with mild PD. Furthermore, the
results may be highly generalizable as the intervention is
studied in its natural setting and the recruitment strategies
of both the study and the community mental health cen-
tres that offer the course are very similar. Another strength
of this trial is the use of an structured diagnostic interview
for DSM-IV and ICD-10 psychiatric disorders (MINI-
Plus). This makes it possible to analyze changes in PD sta-
tus, and for randomization to be stratified by subthresh-
old PD versus mild PD, and by presence versus absence of
co-occurring agoraphobia. The latter was done because it
was assumed that agoraphobia is a prognostic relevant
factor for treatment response in PD.
We recognize a number of limitations in this study. First,
because of the absence of a placebo control, it is not clear
whether nonspecific components of the intervention,
such as social cohesion and expectation of gain contribute
to the possible early intervention effect. Future research
should use placebo controlled designs to overcome this
problem. Secondly, the time available to study a change in
PD status was only three months. For ethical reasons the
control group received the intervention a few weeks after
T1. For future research to study a change in PD status an
extended period is advised. Thirdly, because of financial
limitations we could not raise the sample size, so the
change of protocol by including mild PD caused a lack of
power to analyze a reduction of incidence of PD according
to the MINI-Plus. Fourthly, there is no control condition
at six-month follow-up after the course. Therefore, defi-
nite conclusions that the possible effects at six-month fol-
low-up may be related to the intervention are not allowed.
Finally, the extended follow-up period was only six
months following the conclusion of the course, but longer
follow-up periods are needed to know how long the pos-
sible effects will persist.Page 7 of 9
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research of an early intervention in panic disorder – a
severe and persistent mental disorder, associated with a
large burden of disease and extensive economic costs – is
of the utmost importance.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors contributed to the design of the study. PM and
GW drafted the manuscript and took care of the recruit-
ment of participants and data collection. FS, GW, PS and
PM will perform the statistical analyses. PC, AvB and PS
will act as a Quality Assurance Committee for this trial. All
authors provided comments, read and approved the final
manuscript.
Acknowledgements
Supported by the Netherlands Health Research Council, The Hague 
(ZonMw) grant # 50-50110-98-035/6200.0006 (awarded to Dr. Smit). The 
authors thank Ms Jessica Herzmanatus (GGNet) and Ms Rianne van der 
Zanden (Trimbos Institute) for their help with the development of the 
'Don't Panic' intervention; and the trainers and trainees for their valuable 
help in making this study possible.
References
1. Bijl R, De Graaf R, Ravelli A, Smit F, Vollenbergh W: Gender and
age specific first incidence of DSM-III-R psychiatric disorders
in the general population. Results from the Netherlands
Mental Health Survey and Incidence Study (NEMESIS).  Social
Psychiatry and Psychiatric Epidemiology 2002, 37:372-379.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman
S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence
of DSM-III-R psychiatric disorders in the United States.
Results from the National Comorbidity Survey.  Archives of
General Psychiatry 1994, 51:8-19.
3. Eaton WW, Kessler RC, Wittchen HU, Magee WJ: Panic and Panic
Disorder in the United States.  American Journal of Psychiatry 1994,
151:413-420.
4. Harvison K, Woodruff-Borden J, Jeffery S: Mismanagement of
Panic Disorder in Emergency Departments: Contributors,
Costs, and Implications for Integrated Models of Care.  Journal
of Clinical Psychology in Medical Settings 2004, 11(3):217-232.
5. Laitinen-Krispijn S, Bijl R: Mental disorders and employee sick-
ness absence: The Nemesis study.  Social Psychiatry and Psychiatric
Epidemiology 2000, 35:71-77.
6. Marciniak M, Lage M, Landbloom R, Dunayevich E, Bowman L: Med-
ical and Productivity Costs of Anxiety Disorders: Case Con-
trol Study.  Depression and Anxiety 2004, 19:112-120.
7. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, De Graaf R, Beekman
A: Costs of Nine Common Mental Disorders: Implications
for Curative and Preventive Psychiatry.  J Ment Health Policy
Econ 2006, 9(4):193-200.
8. Norton GR, Cox BJ, Malan J: Nonclinical panickers: A critical
review.  Clinical Psychology Review 1992, 12:121-139.
9. Reed V, Wittchen HU: DSM IV panic attacks and panic disorder
in a community sample of adolescents and young adults: how
specific are panic attacks?  Journal of Psychiatric Research 1998,
32:335-345.
10. Batelaan N, De Graaf R, Van Balkom A, Vollebergh W, Beekman A:
Thresholds for health and thresholds for illness: panic disor-
der versus subthreshold panic disorder.  Psychological Medicine
2007, 37:247-256.
11. Norton GR, Dorward J, Cox BJ: Factors associated with panic
attacks in nonclinical subjects.  Behavior Therapy 1986,
17:239-252.
12. Ehlers A: A 1-year prospective study of panic attacks: Clinical
course and factors associated with maintenance.  Journal of
Abnormal Psychology 1995, 104:164-172.
13. Katerndahl DA: Progression of limited symptom attacks.
Depression and Anxiety 1999, 9:138-140.
14. Furukawa TA, Watanabe N, Churchill R: Psychotherapy plus anti-
depressant for panic disorder with or without agoraphobia.
British Journal of Psychiatry 2006, 188:305-312.
15. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H: Utilising
survey data to inform public policy: comparison of the cost-
effectiveness of treatment of ten mental disorders.  British
Journal of Psychiatry 2004, 184:526-533.
16. Liebowitz MR: Panic Disorder as a Chronic Illness.  The Journal of
Clinical Psychiatry 1997, 58(Suppl 13):5-8.
17. Dadds MR, Spence SH, Holland DE, Barrett PM, Laurens KR: Preven-
tion and early intervention for anxiety disorders: A control-
led trial.  Journal of Consulting and Clinical Psychology 1997,
65:627-635.
18. Schmidt NB, Eggleston AM, Woolaway-Bickel K, Fitzpatrick KK,
Vasey MW, Richey JA: Anxiety Sensitivity Amelioration Train-
ing (ASAT): A longitudinal primary prevention program tar-
geting cognitive vulnerability.  Journal of Anxiety Disorders 2007,
21:302-319.
19. Seligman MEP, Schulman P, DeRubeis RJ, Hollon SD: The preven-
tion of depression and anxiety.  Prevention and Treatment 1999,
2(1): [http://journals.apa.org/prevention/volume2/
pre0020008a.html].
20. Gardenswartz CA, Craske MG: Prevention of Panic Disorder.
Behavior Therapy 2001, 32:725-737.
21. Reiss S, Peterson RA, Gursky M, McNally RJ: Anxiety, sensitivity,
anxiety frequency, and the prediction of fearfulness.  Behaviour
Research and Therapy 1986, 24:1-8.
22. World Health Organization: Composite International Diagnostic Inter-
view (CIDI), Version 2.1 Geneva: WHO; 1997. 
23. Swinson RP, Soulios C, Cox BJ, Kuch K: Brief treatment of emer-
gency room patients with panic attacks.  Am J Psychiatry 1992,
149(7):944-946.
24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller
E, Hergueta T, Baker R, Dunbar GC: The Mini International Neu-
ropsychiatric Interview (MINI): The development and vali-
dation of structured diagnostic psychiatric interview for
DSM-IV and ICD-10.  Journal of Clinical Psychiatry 1998, 59(Suppl
20):22-33.
25. Shear MK, Rucci P, Williams J, Frank E, Grochocinski V, Vander Bilt J,
Houck P, Wang T: Reliability and validity of the panic disorder
severity scale: replication and extension.  Journal of Psychiatric
Research 2001, 35:293-296.
26. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer
D, Micev V, Paunovic VR, Timotijevic I, Sarkar N, Skoglund L, Pem-
berton SC: Efficacy of usual antidepressant dosing regimens of
fluoxetine in panic disorder: randomised, placebo-controlled
trial.  The British Journal of Psychiatry 2001, 179:514-518.
27. Bakker A: Recente ontwikkelingen in de behandeling van
paniekstoornis en agorafobie [Recent developments in the
treatment of panic disorder and agoraphobia].  Tijdschrift voor
Psychiatrie (Dutch Journal of Psychiatry) 2001, 43(6):385-393.
28. Margraf J, Barlow DH, Clark DM, Telch MJ: Psychological treat-
ment of panic: Works in progress on outcome, active ingre-
dients, and follow-up.  Behaviour Research and Therapy 1993,
31:1-8.
29. Van Balkom AJLM, Bakker A, Spinhoven P, Blaauw BMJW, Smeenk S,
Ruesink B: A meta-analysis of the treatment of panic disorder
with or without agoraphobia: A comparison of psychophar-
macological, cognitive-behavioral, and combination treat-
ments.  Journal of Nervous and Mental Disease 1997, 185:510-516.
30. Meulenbeek P, Herzmanatus J, Smit F, Willemse G, Van der Zanden
R: Draaiboek: Geen Paniek, leren omgaan met paniekklachten Utrecht:
Trimbos-instituut/GGNet; [Manual: Don't Panic, learn to cope with
panic complaints]; 2005. 
31. Meulenbeek P, Herzmanatus J, Smit F, Willemse G, Van der Zanden
R: Cursusmap: Geen Paniek, leren omgaan met paniekklachten Utrecht:
Trimbos-instituut/GGNet; [Workbook: Don't Panic, learn to cope
with panic complaints]; 2005. 
32. Meer A Van der, Burgerhout K: Nederlandse versie van de Panic Disor-
der Severity Scale Amsterdam: Universiteit van Amsterdam; [Dutch
version of the Panic Disorder Severity Scale]; 2004. Page 8 of 9
(page number not for citation purposes)
Trials 2008, 9:67 http://www.trialsjournal.com/content/9/1/67Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
33. Houck PR, Spiegel DA, Shear MK, Rucci P: Reliability of the self-
report version of the panic disorder severity scale.  Depression
and Anxiety 2002, 15:183-185.
34. Van Vliet IM, Leroy H, Van Megen HJGM: MINI Plus: MINI Internation-
aal Neuropsychiatrisch Interview: Dutch version 50.0 (in Dutch) Leiden:
LUMC; 2000. 
35. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV: Assessing
psychiatric impairment in primary care with the Sheehan
Disability Scale.  International Journal of Psychiatry in Medicine 1997,
27:93-105.
36. Rohde P, Lewinsohn PM, Seely JR: Comparability of telephone
and face-to-face interviews in assessing axis I and II disor-
ders.  American Journal of Psychiatry 1997, 154:1593-1598.
37. Evans M, Kessler D, Lewis G, Peters TJ, Sharp D: Assessing mental
health in primary care research using standardized scales:
can it be carried out over the telephone?  Psychological Medicine
2004, 34:157-162.
38. Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C: The
Mobility Inventory for Agoraphobia.  Behaviour Research and
Therapy 1985, 23:35-44.
39. De Beurs E: The assessment and treatment of panic disorder and agora-
phobia Amsterdam: Thesis Publications; 1993. 
40. Zigmond AS, Sniath RP: The Hospital Anxiety and Depression
Scale.  Acta Psychiatrica Scandinavica 1983, 67:361-370.
41. Spinhoven P, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM,
Van Hemert AM: A validation study of the Hospital Anxiety
and Depression Scale (HADS) in different groups of Dutch
subjects.  Psychological Medicine 1997, 27:363-370.
42. Telch MJ, Brouillard M, Telch CF, Agras WS, Taylor CB: Role of
Cognitive Appraisal in Panic-Related Avoidance.  Behaviour
Research and Therapy 1989, 27:373-383.
43. De Beurs E, Smit JH, Comijs HC: The Panic Opinion List (POL).
The reliability and validity of a cognitive measure for panic
disorder (in Dutch).  Gedragstherapie (Dutch Journal of Behaviour
Therapy) 2005, 38:141-154.
44. Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inven-
tory-II San Antonio, TX: Psychological Corporation; 1996. 
45. Van der Does AJW: The Dutch version of the Beck Depression Inventory-
second edition (BDI-II-NL) (in Dutch) Lisse: Swets Test Publishers; 2002. 
46. Richter P, Werner J, Heerlein A, Kraus A, Sauer H: On the validity
of the Beck Depression Inventory: A review.  Psychopathology
1998, 31:160-168.
47. Pearlin LI, Schooler C: The structure of coping.  Journal of Health
and Social Behavior 1978, 19:2-21.
48. Brooks R, EuroQol Group: EuroQol: the current state of play.
Health Policy 1996, 37:53-72.
49. Lambert MJ, Burlingame GM, Umphress V, Hansen NB, Vermeersch
DA, Clouse GC, Yanchar SC: The Reliability and Validity of the
Outcome Questionnaire.  Clinical Psychology and Psychotherapy
1996, 3:249-258.
50. de Beurs E, den Hollanders-Gijsman ME, Buwalda V, Trijsburg W, Zit-
man FG: The Outcome Questionnaire OQ-45. Psychodiag-
nostic instrument (in Dutch).  De Psycholoog (Dutch Journal The
Psychologist) 2005, 40:393-400.
51. Hakkaart-Van Roijen L, Van Straten A, Donker M: Manual Trimbos/
iMTA questionnaire for costs associated with psychiatric ill-
ness (TIC-P, in Dutch).  Rotterdam: Erasmus University; 2002. 
52. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Devel-
opment of the Alcohol Use Disorders Identification Test
(AUDIT). WHO collaborative project on early detection of
persons with harmful alcohol consumption 1993.  Addiction
1993, 88:791-804.
53. Meyer B, Pilkonis PA, Krupnick JL, Egan MK, Simmens SJ, Sotsky SM:
Treatment expectancies, patient alliance and outcome: Fur-
ther analyses from the National Institute of Mental Health
Treatment of Depression Collaborative Research Program.
Journal of Consulting & Clinical Psychology 2002, 70:1051-1055.
54. Bradley KA, Bush KR, McDonell MB, Malone T, Fihn SD: Screening
for problem drinking: comparison of CAGE and AUDIT.  Jour-
nal of General Internal Medicine 1998, 13:379-388.
55. Devilly GJ, Borkovec TD: Psychometric properties of the cred-
ibility/expectancy questionnaire.  Journal of Behavior Therapy and
Experimental Psychiatry 2000, 31:73-86.
56. Everitt BS: Modern medical statistics: a practical guide New York:
Oxford University Press; 2003. 
57. Demirtas H: Simulation driven inferences for multiply
imputed longitudinal datasets.  Statistica Neerlandica 2004,
58:466-482.
58. StataCorp LP: Stata Statistical Software: Release 9.0.  In College
Station Texas: Stata Corporation; 2005. 
59. Lipsey MW, Wilson DB: The efficacy of psychological, educa-
tional and behavioral treatment.  American Psychologist 1993,
48:1181-1209.
60. Jacobson NS, Truax P: Clinical Significance: A Statistical
Approach to Defining Meaningful Change in Psychotherapy
Research.  Journal of Consulting and Clinical Psychology 1991,
59(1):12-19.
61. Greeven A, Van Balkom AJLM, Visser S, Merkelbach JW, Van Rood
YR, Van Dyck R, Van der Does AJW, Zitman FG, Spinhoven P: Cog-
nitive Behavior Therapy and Paroxetine in the Treatment of
Hypochondriasis: A Randomized Controlled Trial.  American
Journal of Psychiatry 2007, 164:91-99.
62. Haringsma R, Engels GI, Cuijpers P, Spinhoven Ph: Effectiveness of
the Coping with Depression course for older adults provided
by the community-based mental health care system in the
Netherlands: a randomized controlled field trial.  International
Psychogeriatrics 2006, 18:307-325.
63. Allart-van Dam E: Indicated prevention of depression and pre-
diction of outcome: The 'Coping with Depression' Course.  In
PhD thesis Nijmegen: Katholieke Universiteit Nijmegen; 2003. 
64. Bohlmeijer E, Valenkamp M, Westerhof G, Smit F, Cuijpers P: Crea-
tive reminiscence as an early intervention for depression:
results of a pilot project.  Aging & Mental Health 2005,
9(4):302-304.Page 9 of 9
(page number not for citation purposes)
